. 2017 Sep 8;2(4):615–623. doi: 10.1016/j.adro.2017.09.005

Table 1.

Patient/treatment characteristics

Clinical variable/treatment factor	Number of patients	%
Sex
Male	63	67.0
Female	31	33.0
Malignancy
Prostate	50	53.2
Primary	37	39.4
Postoperative	11	11.7
Recurrence	2	2.1
Bladder	12	12.8
Primary	8	8.5
Postoperative	0	0
Recurrence	4	4.3
Uterus	7	7.4
Primary	5	5.3
Postoperative	0	0
Recurrence	2	2.1
Ovary	6	6.4
Primary	1	1.1
Postoperative	0	0
Recurrence	5	5.3
Pancreas	6	6.4
Primary	4	4.3
Postoperative	1	1.1
Recurrence	1	1.1
Other	13	13.8
Image Guided Radiation Therapy
Yes	32	34.0
Cone beam computed tomography	23	24.5
kV	9	9.6
No	62	66.0
Diabetes Mellitus
Yes	23	24.5
No	69	73.4
Not available	2	2.1
Hypertension
Yes	36	38.3
No	56	59.6
Not available	2	2.1
Chemotherapy
Any	37	39.4
Cisplatin	17	18.1
Capecitabine/5-fluorouracil	12	12.8
Other	8	8.5
Concurrent	29	30.9
Cisplatin	14	14.9
Capecitabine/5-fluorouracil	9	9.6
Other	6	6.4
None	57	60.6
Androgen Deprivation Therapy (Male Patients Only)
Any	34	36.2
Concurrent	32	34.0
None	29	30.1
Previous Gastrointestinal Conditions
Yes	35	37.2
No	57	60.6
Not available	2	2.1
Previous Abdominal Surgery
Yes	37	39.4
No	55	58.5
Not available	2	2.1
Vascular Disease
Yes	16	17.0
No	76	80.9
Not available	2	2.1
Constructed Dose-Volume Histogram Groups
V₈₀ >0 cc	2	2.2^a
V₇₅ >1 cc	5	5.4^a
V₇₅ >0 cc	12	13.0^a
V₇₀ >1 cc	13	14.1^a
V₇₀ >0 cc	22	23.9^a
V₆₅ >1 cc	33	35.9^a
V₆₅ >0 cc	50	54.3^a
V₆₀ >1 cc	49	53.3^a
V₆₀ >0 cc	65	70.7^a

These percentages were calculated using 92 in the denominator because 2 patients received multiple sets of radiation therapy and their dose-volume histograms could not be appropriately summed together.